COMPASS Pathways PLC (CMPS)
| Market Cap | 436.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.20M |
| Shares Out | 42.51M |
| EPS (ttm) | -1.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,304 |
| Open | 10.44 |
| Previous Close | 10.38 |
| Day's Range | 10.04 - 10.44 |
| 52-Week Range | 6.54 - 49.52 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 69.36 (+575.4%) |
| Earnings Date | Aug 10, 2022 |
About CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Ki... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is 69.36, which is an increase of 575.37% from the latest price.
News
Wall Street Analysts See a 781% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This H...
The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric i...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression
COMPASS Pathways to participate in upcoming Citi's Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investme...
LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announc...
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental hea...
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
London, UK – 9 May 2022
COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announc...
COMPASS Pathways to participate in Needham Healthcare conference
LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, annou...
COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
Pioneering c ollaboration with King's College London and South London and Maudsley NHS Foundation Trust
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovat...
COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022
LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in menta...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resist...
London, UK and New York, US, 19 January 2022
COMPASS Pathways to participate in H.C. Wainwright investor conference
LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announ...
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support
3 Psychedelic Stocks to Play the Shroom Boom
Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective as of ma...
COMPASS Selected for Addition to NASDAQ Biotechnology Index
London, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, ...
COMPASS Pathways announces changes in Executive Team
M atthew Owen s appointed General Counsel and Chief Legal Officer ;
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) announced Monday it had achieved positive results from its exploratory study of COMP360 psilocybin therapy in conjunction...
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in ...
London, UK – 13 December 2021
Michael Falvey joins COMPASS Pathways as Chief Financial Officer
London, UK - 3 December 2021
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to...
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 ps...
- Positive topline results validated by additional analyses
COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences
LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announ...